Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.33B | $2.99B | $3.19B | $3.08B | $2.96B | $2.77B | $2.91B | $2.77B |
| Cost of revenue | $489.20M | $392.80M | $466.00M | $414.80M | $407.50M | $363.00M | $423.40M | $392.60M |
| Gross profit | $2.84B | $2.59B | $2.72B | $2.66B | $2.56B | $2.41B | $2.49B | $2.38B |
| Gross margin | 85.3% | 86.8% | 85.4% | 86.5% | 86.3% | 86.9% | 85.5% | 85.8% |
| Research and development | $993.80M | $961.60M | $973.70M | $977.70M | $978.40M | $979.70M | $998.70M | $875.90M |
| Selling, general and administrative | $582.20M | $493.70M | $487.00M | $445.10M | $424.60M | $396.40M | $377.60M | $371.80M |
| Operating expenses | $1.60B | $1.46B | $1.52B | $1.48B | $1.41B | $1.78B | $1.46B | $1.26B |
| Operating income | $1.25B | $1.14B | $1.21B | $1.19B | $1.15B | $630.10M | $1.03B | $1.12B |
| Operating margin | 37.4% | 38.1% | 37.8% | 38.6% | 38.8% | 22.7% | 35.2% | 40.3% |
| EBITDA | $1.32B | $1.19B | $1.32B | $1.29B | $1.21B | $1.08B | $1.16B | $1.18B |
| Interest income | $120.60M | $114.80M | $121.90M | $125.70M | $118.70M | $117.90M | $128.20M | $132.20M |
| Interest expense | $0 | $0 | −$3.30M | −$3.30M | $0 | $0 | −$2.80M | −$7.50M |
| Income before taxes | $1.39B | $1.25B | $1.33B | $1.30B | $1.28B | $730.40M | $1.14B | $1.22B |
| Income taxes | $292.00M | $221.50M | $139.90M | $215.90M | $250.10M | $84.10M | $223.50M | $178.70M |
| Net income | $1.10B | $1.03B | $1.19B | $1.08B | $1.03B | $646.30M | $913.00M | $1.05B |
| Net margin | 33.0% | 34.5% | 37.3% | 35.2% | 34.8% | 23.3% | 31.4% | 37.7% |
| EPS, basic | $4.34 | $4.06 | $4.70 | $4.24 | $4.02 | $2.52 | $3.55 | $4.05 |
| EPS, diluted | $4.31 | $4.02 | $4.65 | $4.20 | $3.99 | $2.49 | $3.63 | $4.01 |
| Diluted shares | 255.20M | 256.30M | 256.00M | 257.60M | 258.90M | 259.50M | 251.40M | 261.00M |
Figures describe Vertex Pharmaceuticals shares, not any token. As of Aug 4, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.